Humacyte, Inc. (HUMA)

NASDAQ: HUMA · IEX Real-Time Price · USD
3.05
-0.04 (-1.29%)
Nov 29, 2022 3:20 PM EDT - Market open
-1.29%
Market Cap 318.63M
Revenue (ttm) 1.74M
Net Income (ttm) 34.34M
Shares Out 103.03M
EPS (ttm) 2.86
PE Ratio 1.07
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 162,761
Open 3.08
Previous Close 3.09
Day's Range 2.93 - 3.11
52-Week Range 2.78 - 11.34
Beta 1.01
Analysts Buy
Price Target 11.30 (+270.5%)
Earnings Date Nov 10, 2022

About HUMA

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfoli... [Read more]

Industry Biotechnology
Founded 2004
Employees 145
Stock Exchange NASDAQ
Ticker Symbol HUMA
Full Company Profile

Financial Performance

In 2021, Humacyte's revenue was $1.26 million, a decrease of -15.29% compared to the previous year's $1.49 million. Losses were -$26.48 million, -60.20% less than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for HUMA stock is "Buy." The 12-month stock price forecast is 11.3, which is an increase of 270.49% from the latest price.

Price Target
$11.3
(270.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference

DURHAM, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial...

6 days ago - GlobeNewsWire

Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -19.05% and 88.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Humacyte Third Quarter 2022 Financial Results and Business Update

-- Progress Continues in Clinical Development of Human Acellular Vessel™ (HAV™) for Vascular Trauma; BLA Filing Anticipated mid 2023 –

2 weeks ago - GlobeNewsWire

Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American H...

Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels

3 weeks ago - GlobeNewsWire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022

DURHAM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue, complex tiss...

3 weeks ago - GlobeNewsWire

The 7 Best Stocks Under $20 to Buy Now

When it comes to the best stocks under $20, let's be real with each other — generally speaking, you get what you pay for. In other words, you don't want to be the person that downgrades a two-star hotel...

Other symbols: AMCRDBRGINFYSPOKWIT
1 month ago - InvestorPlace

Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascula...

HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mi...

2 months ago - GlobeNewsWire

Humacyte Expands Board of Directors and Leadership Team with New Appointments

Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors

2 months ago - GlobeNewsWire

Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the I...

Dr. Todd E. Rasmussen provides HAV™ clinical update and surgical skills workshop at ICMM Dr. Todd E. Rasmussen provides HAV™ clinical update and surgical skills workshop at ICMM

2 months ago - GlobeNewsWire

Humacyte Presents at Multiple Conferences in September 2022

DURHAM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and complex...

2 months ago - GlobeNewsWire

Wall Street Analysts See an 85% Upside in Humacyte, Inc. (HUMA): Can the Stock Really Move This High?

The consensus price target hints at an 84.8% upside potential for Humacyte, Inc. (HUMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est...

3 months ago - Zacks Investment Research

Humacyte Second Quarter 2022 Financial Results and Business Update

-- Human Acellular Vessels™ (HAVs™) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs –

3 months ago - GlobeNewsWire

Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022

DURHAM, N.C., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial...

3 months ago - GlobeNewsWire

Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) ...

-- Preclinical model data expected to support development of small diameter HAV to treat patients with coronary artery disease-- -- Small-diameter HAV observed to maintain patency and exhibit host-cell ...

4 months ago - GlobeNewsWire

Humacyte Announces Presentation of Preclinical Data on the HAV™ in Coronary Artery Bypass Grafting at the Basic Cardi...

DURHAM, N.C., July 19, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, today annou...

4 months ago - GlobeNewsWire

Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma

Thursday, July 14, 2022 @ 11:30 a.m. ET Thursday, July 14, 2022 @ 11:30 a.m. ET

4 months ago - GlobeNewsWire

Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascul...

-- HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma –

5 months ago - GlobeNewsWire

Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.

Industry leader brings deep expertise in international drug development, strategic leadership, and corporate partnering for biopharmaceutical companies Industry leader brings deep expertise in internati...

5 months ago - GlobeNewsWire

Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV...

-- Successful first two HAV implantations in wounded Ukrainian citizens

5 months ago - GlobeNewsWire

Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)

-- Data indicate HAV does not stimulate increase in panel reactive antibodies, an adaptive immune response correlated with increased risk of implant failure -- -- Data presented today in IMPACT session ...

5 months ago - GlobeNewsWire

Humacyte to Present at the H.C. Wainwright Global Investment Conference

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial ...

6 months ago - GlobeNewsWire

Humacyte First Quarter 2022 Financial Results and Business Update

-- Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries -- -- Strengthened leadership team with appointment of Shamik Pari...

6 months ago - GlobeNewsWire

Humacyte to Provide Human Acellular Vessels™ (HAVs™) to Front-line Hospitals in Ukraine for Treatment of Vascular Tra...

-- First shipment of HAVs to six Ukrainian hospitals made today -- -- Product candidate to be used for civilian and military vascular trauma repair, the HAV's lead investigational indication --

6 months ago - GlobeNewsWire

Humacyte to Present First Quarter 2022 Financial Results and Provide Recent Corporate Update on May 13, 2022

DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial ...

6 months ago - GlobeNewsWire

Humacyte Expands Leadership Team with Appointment of Shamik Parikh, M.D., as Chief Medical Officer

--Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle-- --Key appointment as Humacyte advances HAV through multiple l...

7 months ago - GlobeNewsWire